STUDY

A ranking put Skyrizi ahead of Humira, but some of its numbers don't match

“Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.” Abdullah A, Polus L. Cureus. April 2026

Abdullah A, Polus L · Cureus · April 2026

Network meta-analysis
The finding

This network analysis ranked risankizumab above adalimumab for week-16 skin response. A reported sample size does not match the original trial, limiting confidence in the pooled ranking.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Network meta-analysis of published trials. The authors linked direct and indirect comparisons of biologics for moderate to severe plaque psoriasis.
At a glance

Who was studied and for how long

Reported trials
11
The paper describes 10 datasets
Outcome
PASI 90
Measured at week 16
Compared
Six biologics
Also included placebo
What they did

How the study worked

Find trialsThe authors searched for phase 3 trials.
Build a networkThey linked treatments through common comparators.
Rank outcomesThe analysis compared the odds of reaching a 90% improvement on the psoriasis score.
What they found

The results

Reported rankings

The analysis ranked bimekizumab first and risankizumab second for PASI 90 at week 16. It ranked both above adalimumab.

Reporting discrepancy

The paper lists 507 participants for IMMvent. The original trial reports 605 randomized. The pooled paper does not clearly reconcile the difference.

A ranking is not an effect size. The original IMMvent randomized comparison provides the clearer answer for risankizumab versus adalimumab.
How much to trust it

Strengths and limits

Strengths

  • Used a common short-term outcome
  • Included multiple phase 3 trials

Limits

  • Several comparisons are indirect
  • Participant counts do not reconcile clearly with the original IMMvent report
  • The review covers only week-16 skin response
Limited confidence. The ranking is hard to interpret because the trial reporting is inconsistent.
What it means for you

The takeaway

Check the original trial

The analysis offers context across biologics. The direct IMMvent trial gives a clearer comparison for these two medicines.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

PASI 90

A 90% or larger reduction in the Psoriasis Area and Severity Index.

Network meta-analysis

A pooled analysis connecting treatments across trials, often through shared comparators.

Original source

Abdullah A, Polus L. Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.. Cureus. 2026;18(4):e107459.

PMID 42181314